Literature DB >> 11573047

Results of hepatic resection for sarcoma metastatic to liver.

R P DeMatteo1, A Shah, Y Fong, W R Jarnagin, L H Blumgart, M F Brennan.   

Abstract

OBJECTIVE: To evaluate the outcome of patients with liver metastases from sarcoma who underwent hepatic resection at a single institution and were followed up prospectively. SUMMARY BACKGROUND DATA: The value of hepatic resection for metastatic sarcoma is unknown.
METHODS: There were 331 patients with liver metastases from sarcoma who were admitted to Memorial Hospital from 1982 to 2000, and 56 of them underwent resection of all gross hepatic disease. Patient, tumor, and treatment variables were analyzed to assess outcome.
RESULTS: Of the 56 patients who underwent complete resection, 34 (61%) had gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Half of the patients required an hepatic lobectomy or extended lobectomy. There were no perioperative deaths in the completely resected group, although 3 of the 75 patients who underwent exploration (4%) died. The postoperative 1-, 3-, and 5-year actuarial survival rates were 88%, 50%, and 30%, respectively, with a median of 39 months. In contrast, the 5-year survival rate of patients who did not undergo complete resection was 4%. On multivariate analysis, a time interval from the primary tumor to the development of liver metastasis greater than 2 years was a significant predictor of survival after hepatectomy.
CONCLUSIONS: Complete resection of liver metastases from sarcoma in selected patients is associated with prolonged survival. Hepatectomy should be considered when complete gross resection is possible, especially when the time to the development of liver metastasis exceeds 2 years.

Entities:  

Mesh:

Year:  2001        PMID: 11573047      PMCID: PMC1422077          DOI: 10.1097/00000658-200110000-00013

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  25 in total

1.  Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients.

Authors:  L E Harrison; M F Brennan; E Newman; J G Fortner; A Picardo; L H Blumgart; Y Fong
Journal:  Surgery       Date:  1997-06       Impact factor: 3.982

2.  Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine.

Authors:  G M Mavligit; A A Zukwiski; L M Ellis; V P Chuang; S Wallace
Journal:  Cancer       Date:  1995-04-15       Impact factor: 6.860

3.  Hepatic transplantation for primary and metastatic cancers of the liver.

Authors:  I Penn
Journal:  Surgery       Date:  1991-10       Impact factor: 3.982

4.  Surgery for disseminated abdominal sarcoma.

Authors:  C P Karakousis; L E Blumenson; G Canavese; U Rao
Journal:  Am J Surg       Date:  1992-06       Impact factor: 2.565

Review 5.  Hepatic metastases from soft-tissue sarcoma.

Authors:  D P Jaques; D G Coit; E S Casper; M F Brennan
Journal:  Ann Surg       Date:  1995-04       Impact factor: 12.969

6.  Hepatic resection for metastatic neuroendocrine carcinomas.

Authors:  F G Que; D M Nagorney; K P Batts; L J Linz; L K Kvols
Journal:  Am J Surg       Date:  1995-01       Impact factor: 2.565

7.  Liver transplantation for malignant disease. Results in 93 consecutive patients.

Authors:  J G O'Grady; R J Polson; K Rolles; R Y Calne; R Williams
Journal:  Ann Surg       Date:  1988-04       Impact factor: 12.969

8.  Assessment of five-year experience with abdominal organ cluster transplantation.

Authors:  M Alessiani; A Tzakis; S Todo; A J Demetris; J J Fung; T E Starzl
Journal:  J Am Coll Surg       Date:  1995-01       Impact factor: 6.113

9.  Resection of colorectal liver metastases.

Authors:  J Scheele; R Stang; A Altendorf-Hofmann; M Paul
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

Review 10.  Hepatic resection for noncolorectal nonneuroendocrine metastases.

Authors:  S I Schwartz
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  71 in total

1.  Advances in the surgical management of gastrointestinal stromal tumor.

Authors:  Umer I Chaudhry; Ronald P DeMatteo
Journal:  Adv Surg       Date:  2011

2.  [Therapeutic management of intra-abdominal and retroperitoneal soft tissue sarcomas].

Authors:  S Wong; M F Brennan
Journal:  Chirurg       Date:  2004-12       Impact factor: 0.955

3.  Reported outcome factors for hepatic metastasectomy.

Authors:  N Joseph Espat
Journal:  J Gastrointest Surg       Date:  2006-02       Impact factor: 3.452

4.  Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome.

Authors:  Joseph Kim; Takuji Mori; Steven L Chen; Farin F Amersi; Steve R Martinez; Christine Kuo; Roderick R Turner; Xing Ye; Anton J Bilchik; Donald L Morton; Dave S B Hoon
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

5.  The Utility of Endoscopic Ultrasound-Guided Brachytherapy in Liver Metastasis: A Case Report and Review of the Literature.

Authors:  Nayana E George; Benjamin Tharian; Helen Lyo; Apoorva Jayarangaiah; Irini Youssef; Joie Singh; Samy I McFarlane; Shivakumar Vignesh
Journal:  Am J Med Case Rep       Date:  2018-10-14

6.  Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate.

Authors:  Seiji Suzuki; Koji Sasajima; Masayuki Miyamoto; Hidehiro Watanabe; Tadashi Yokoyama; Hiroshi Maruyama; Takeshi Matsutani; Aimin Liu; Masaru Hosone; Shotaro Maeda; Takashi Tajiri
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

7.  The impact of 18F-FDG PET/CT in patients with liver metastases.

Authors:  Siew C Chua; Ashley M Groves; Irfan Kayani; Leon Menezes; Svetislav Gacinovic; Yong Du; Jamshed B Bomanji; Peter J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-23       Impact factor: 9.236

8.  [Uterine sarcoma treatment].

Authors:  G Köhler
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

9.  Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics.

Authors:  Stephanie E W Punt; Janet F Eary; Janet O'Sullivan; Ernest U Conrad
Journal:  Nucl Med Commun       Date:  2009-07       Impact factor: 1.690

Review 10.  Multidisciplinary treatment of gastrointestinal stromal tumors.

Authors:  T Peter Kingham; Ronald P DeMatteo
Journal:  Surg Clin North Am       Date:  2009-02       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.